FDA Mulls Alternative Approval Path, Feedback Mostly Positive
By Catherine Shaffer
Monday, February 4, 2013
The FDA convened a public hearing to receive input on its proposal to expedite development of new drugs for serious or life-threatening conditions with unmet need. The pathway would involve smaller, faster clinical trials with narrow, tightly enforced labeling for use in patients without other options.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.